IMedicor signs agreement with Access Pharmaceuticals for the North American commercial launch of MuGard
iMedicor today announced it has signed an agreement with Dallas-based Access Pharmaceuticals for the North American commercial launch of MuGard, its FDA-approved oral wound rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.
iMedicor, a Nanuet-based company that specializes in electronic medica records, said that it has formed a partnership with PhoneTag, a New York-based voicemail services company.